The biotech’s gene therapy isn’t helping patients see better.
The cannabis-focused biotech couldn’t hold its post-earnings gains.
Down over 18%, the biotech bounces back.
Investors continue to worry about decelerating growth at the orthodontic-device specialist.
It’s rejected a pair of drugs in the last six months.
It was a roller coaster of a month for the biotech.
Manufacturing issues plague the start-up.
The women’s health expert logged a solid second quarter.
The U.S. government wants more of its smallpox vaccine.
How much Johnson & Johnson will actually benefit is unclear.
The biotech got good news on a clinical trial.
Investors appear to have some confidence that the companies will settle their opioid lawsuits.
Positive clinical-trial results couldn't save the embroiled biotech.
The second quarter wasn't too shabby either.
The company is undergoing a review of strategic alternatives.
Royalties are nice, but licensing, milestone, and option payments are getting it done for this biotech.
The medical device maker looks to round out its fiscal year with a bang.
The biotech could go from one to four marketed drugs in a little over a year.
Developing novel drugs takes time.
Zynteglo was recently approved in Europe.